Navidea Biopharmaceuticals has received a U.S. patent for its radiolabeled agent that binds to dopamine transporter receptors. The patent for NAV5001 covers the formulation of the tracer, which is used with SPECT to diagnose Parkinsonian syndromes and dementia with Lewy bodies. Phase III clinical trials of NAV5001 are expected to start by the end of the year.

Related Summaries